Design of a tetravalent dengue vaccine incorporating T-cell epitopes from NS3 and NS5 proteins and B-cell epitopes from the envelope protein using an immunoinformatics approach.
- 1Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Abstract
Dengue virus remains a major global health threat due to its four antigenically diverse serotypes and limited treatment and vaccine options. This study aimed to design and evaluate a rational tetravalent multi-epitope vaccine capable of eliciting broad cross-serotype immune responses against dengue virus. An immunoinformatics-driven strategy was employed to identify CTL, HTL, and B-cell epitopes from the NS3, NS5, and envelope domain III proteins of DENV-1 to DENV-4 based on antigenicity, allergenicity, and predicted immunogenic potential, followed by assessment of HLA population coverage. Among the selected CTL epitopes, three were completely conserved across all four serotypes, while one HTL epitope showed the highest conservation among the selected MHC class II epitopes. High-scoring linear B-cell epitopes were identified across EDIII of all four DENV serotypes, with several closely matching experimentally validated epitopes and predominantly localizing to the FG loop and DIII-DI hinge regions. The combined MHC class I and II population coverage reached 98.05% worldwide. The final vaccine construct comprised 584 amino acids incorporating 11 CTL, 14 HTL, and 7 B-cell epitopes linked to an N-terminal β-defensin adjuvant. Molecular docking, MM/GBSA calculations, and 200 ns molecular dynamics simulations demonstrated stable interactions with both TLR2 and TLR4/MD2 complexes, with docking binding energies of -16.2 and -26.0 kcal/mol and MM/GBSA binding free energies of -27.15 ± 0.54 and -52.50 ± 0.55 kcal/mol, respectively. In silico immune simulation predicted substantial lymphocyte activation, enhanced IFN-γ secretion, predicted antigen clearance, and immunoglobulin class switching. Collectively, the proposed tetravalent multi-epitope vaccine was predicted to provide broad cross-serotype epitope representation, substantial population coverage, and favorable structural and immunological profiles, supporting its potential for further vaccine development. Experimental studies in appropriate in vitro and in vivo models are warranted to further assess its immunogenicity, safety, and protective potential.
Related
- Unexpected Localization of AGP Epitopes in the Plastids of Aldrovanda vesiculosa: New Questions About the Distribution of These Epitopes in Angiosperms
- Conserved spike epitopes persist in generalist bat sarbecoviruses
- The TCR Motif Atlas: a database of specificities for TCRs recognizing viral, cancer, and autoimmune epitopes
- In silico characterization of ferritin 2 conserved motifs and B-cell epitopes in Hyalomma anatolicum.
- An Integrative Computational Approach to Predict Viral Epitopes by Targeting the MHC-TCR Complexation
BibTeX
@article{dobutr2026design,
title = {{Design of a tetravalent dengue vaccine incorporating T-cell epitopes from NS3 and NS5 proteins and B-cell epitopes from the envelope protein using an immunoinformatics approach.}},
author = {Theerawat Dobutr and Pemikar Srifa and Nawamin Pinpathomrat},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1934834},
url = {https://europepmc.org/article/MED/42908647},
note = {CC BY},
}
RIS
TY - JOUR
TI - Design of a tetravalent dengue vaccine incorporating T-cell epitopes from NS3 and NS5 proteins and B-cell epitopes from the envelope protein using an immunoinformatics approach.
AU - Theerawat Dobutr
AU - Pemikar Srifa
AU - Nawamin Pinpathomrat
PY - 2026
DA - 2026/10/07
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1934834
UR - https://europepmc.org/article/MED/42908647
AB - Dengue virus remains a major global health threat due to its four antigenically diverse serotypes and limited treatment and vaccine options. This study aimed to design and evaluate a rational tetravalent multi-epitope vaccine capable of eliciting broad cross-serotype immune responses against dengue virus. An immunoinformatics-driven strategy was employed to identify CTL, HTL, and B-cell epitopes from the NS3, NS5, and envelope domain III proteins of DENV-1 to DENV-4 based on antigenicity, allergenicity, and predicted immunogenic potential, followed by assessment of HLA population coverage. Among the selected CTL epitopes, three were completely conserved across all four serotypes, while one HTL epitope showed the highest conservation among the selected MHC class II epitopes. High-scoring linear B-cell epitopes were identified across EDIII of all four DENV serotypes, with several closely matching experimentally validated epitopes and predominantly localizing to the FG loop and DIII-DI hinge regions. The combined MHC class I and II population coverage reached 98.05% worldwide. The final vaccine construct comprised 584 amino acids incorporating 11 CTL, 14 HTL, and 7 B-cell epitopes linked to an N-terminal β-defensin adjuvant. Molecular docking, MM/GBSA calculations, and 200 ns molecular dynamics simulations demonstrated stable interactions with both TLR2 and TLR4/MD2 complexes, with docking binding energies of -16.2 and -26.0 kcal/mol and MM/GBSA binding free energies of -27.15 ± 0.54 and -52.50 ± 0.55 kcal/mol, respectively. In silico immune simulation predicted substantial lymphocyte activation, enhanced IFN-γ secretion, predicted antigen clearance, and immunoglobulin class switching. Collectively, the proposed tetravalent multi-epitope vaccine was predicted to provide broad cross-serotype epitope representation, substantial population coverage, and favorable structural and immunological profiles, supporting its potential for further vaccine development. Experimental studies in appropriate in vitro and in vivo models are warranted to further assess its immunogenicity, safety, and protective potential.
SN - 2235-2988
ER -